FLT3 and acute myeloid leukemia: The ELN recommends consolidation with intermediate-dose cytarabine (IDAC) (1000–1500 mg/m2) alone in non-Flt3 and in combination with Flt3 inhibitors in Flt3 positive AML patients [4].